Structure-based design of novel class II c-Met inhibitors: 2. SAR and kinase selectivity profiles of the pyrazolone series

Journal of Medicinal Chemistry

Volumn 55, Issue 5, 2012, Pages 1868-1897

  Liu, Longbin ^a   Norman, Mark H ^a   Lee, Matthew ^a   Xi, Ning ^a   Siegmund, Aaron ^a   Boezio, Alessandro A ^a   Booker, Shon ^a   Choquette, Debbie ^a   D'Angelo, Noel D ^a   Germain, Julie ^a   Yang, Kevin ^a   Yang, Yajing ^a   Zhang, Yihong ^a   Bellon, Steven F ^a   Whittington, Douglas A ^a   Harmange, Jean Christophe ^a   Dominguez, Celia ^a   Kim, Tae Seong ^a   Dussault, Isabelle ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 458; ANTINEOPLASTIC AGENT; N [4 ((6,7 DIMETHOXYQUINOLIN 4 YL)OXY) 3 FLUOROPHENYL] 1,5 DIMETHYL 3 OXO 2 PHENYL 2,3 DIHYDRO 1H PYRAZOLE 4 CARBOXAMIDE; PROTEIN KINASE INHIBITOR; PYRAZOLONE DERIVATIVE; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ARTICLE; IN VIVO STUDY; NONHUMAN; PROTEIN STRUCTURE; TUMOR XENOGRAFT;

AMINOPYRIDINES; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; GASTRINS; HUMANS; MALE; MICE; MODELS, MOLECULAR; PHOSPHORYLATION; PROTEIN CONFORMATION; PROTO-ONCOGENE PROTEINS C-MET; PYRAZOLES; PYRAZOLONES; RATS; RECEPTOR, IGF TYPE 1; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84863275554     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201331s     Document Type: Article

References (61)

1. Bottaro, D. P.; Rubin, J. S.; Faletto, D. L.; Chan, A. M.; Kmiecik, T. E.; Vande Woude, G. F.; Aaronson, S. A. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product Science 1991, 251, 802-4
2. Naldini, L.; Weidner, K. M.; Vigna, E.; Gaudino, G.; Bardelli, A.; Ponzetto, C.; Narsimhan, R. P.; Hartmann, G.; Zarnegar, R.; Michalopoulos, G. K. Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor EMBO J. 1991, 10, 2867-78
3. Longati, P.; Bardelli, A.; Ponzetto, C.; Naldini, L.; Comoglio, P. M. Tyrosines 1234-1235 are critical for activation of the tyrosine kinase encoded by the MET protoocogene (HGF receptor) Oncogene 1994, 9, 49-57
4. Nakamura, T.; Mizuno, S.; Matsumoto, K.; Sawa, Y.; Matsuda, H.; Nakamura, T. Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF J. Clin. Invest. 2000, 106, 1511-1519
5. Huh, C. G.; Factor, V. W.; Sanchez, A.; Uchida, K.; Commer, E. A.; Thorgeirsson, S. S. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 4477-4482
6. Sattler, M.; Salgia, R. c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy Curr. Oncol. Rep. 2007, 9, 102-108
7. Mazzone, M.; Comoglio, P. M. The Met pathway: master switch and drug target in cancer progression FASEB J. 2006, 20, 1611-1621
8. Matsumoto, K.; Nakamura, T. NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics Cancer Sci. 2003, 94, 321-327
9. Birchmeier, C.; Birchmeier, W.; Gherardi, E.; Vande Woude, G. F. Met, metastasis, motility and more Nature Rev. Mol. Cell Biol. 2003, 4, 915-925
10. Trusolino, L.; Comoglio, P. M. Scatter-factor and semaphorin receptors: cell signaling for invasive growth Nature Rev. Cancer 2002, 2, 289-300
11. Christensen, J.; Burrows, J.; Salgia, R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention Cancer Lett 2005, 225, 1-25
12. Dussault, I.; Kaplan-Lefko, P.; Jun, T.; Coxon, A.; Burgess, T. L. HGF- and c-Met-targeted drugs: hopes, challenges and their future in cancer therapy Drugs Future 2006, 31, 819-825
13. Abidoye, O.; Murukurthy, N.; Salgia, R. Review of clinic trials: agents targeting c-Met Rev. Recent Clin. Trials 2007, 2, 143-147
14. Eder, J. P.; Vande Woude, G. F.; Boerner, S. A.; LoRusso, P. M. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer Clin. Cancer Res. 2009, 15, 2207-2214
15. Cui, J. J. Inhibitors targeting hepatocyte growth factor receptor and their potential therapeutic applications Expert Opin. Ther. Pat. 2007, 17, 1035-1045
16. Porter, J. Small molecule c-Met kinase inhibitors: a review of recent patents Expert Opin. Ther. Pat. 2010, 20, 159-177
17. Schroeder, G. M.; An, Y.; Cai, Z.-W.; Chen, X.-T.; Clark, C.; Cornelius, L. A. M.; Dai, J.; Gullo-Brown, J.; Gupta, A.; Henley, B.; Hunt, J. T.; Jeyaseelan, R.; Kamath, A.; Kim, K.; Lippy, J.; Lombardo, L. J.; Manne, V.; Oppenheimer, S.; Sack, J. S.; Schmidt, R. J.; Shen, G.; Stefanski, K.; Tokarski, J. S.; Trainor, G. L.; Wautlet, B. S.; Wei, D.; Williams, D. K.; Zhang, Y.; Zhang, Y.; Fargnoli, J.; Borzilleri, R. M. Discovery of N -(4-(2-Amino-3- chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1, 2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily J. Med. Chem. 2009, 52, 1251-1254
18. Norman, M. H.; Liu, L.; Lee, M.; Xi, N.; Fellows, I.; D'Angelo, N.; Dominguez, C.; Rex, R.; Bellon, S. F.; Kim, T.-S.; Dussault, I. Structure-based design of novel class II c-Met inhibitors: 1. Identification of pyrazolone-based derivatives. J. Med. Chem. 2012, DOI 10.1021/jm201330u.
19. For the work leading to a clinical candidate based on pyrazolones, see, Liu, L.; Siegmund, A.; Xi, N.; Kaplan-Lefko, P.; Rex, K.; Chen, A.; Lin, J.; Moriguchi, J.; Berry, L.; Huang, L.; Teffera, Y.; Yang, Y.; Zhang, Y.; Bellon, S. F.; Lee, M.; Shimaanovich, R.; Bak, A.; Dominguez, C.; Norman, M.; Harmange, J. C.; Dussault, I.; Kim, T.-S. Discovery of 1-(2-hydroxy-2-methylpropyl)- N -(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2, 3-dihydro-1 H -pyrazole-4-carboxamide (AMG 458): a potent, selective, and orally bioavailable c-Met Inhibitor J. Med. Chem. 2008, 51, 3688-3691
20. Dussault, I.; Bellon, S. F. From concept to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer Anti-Cancer Agents Med. Chem. 2009, 9, 221-229
21. Ronsin, C.; Muscatelli, F.; Mattei, M. G.; Breathnach, R. A novel putative receptor protein tyrosine kinase of the met family Oncogene 1993, 8, 1195-1202
22. Baka, S.; Clamp, A. R.; Jayson, G. C. A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis Expert Opin. Ther. Targets 2006, 10, 867-876
23. Gasparini, G.; Longo, R.; Toi, M.; Ferrara, N. Angiogenic inhibitors: a new therapeutic strategy in oncology Nature Clin. Pract. Oncol. 2005, 2, 562-577
24. Rochester, M. A.; Riedemann, J.; Hellawell, G. O.; Brewster, S. F.; Macaulay, V. M. Silencing of the IGF-1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer Cancer Gene Ther. 2005, 12, 90-100
25. Baserga, R. The insulin-like growth factor-1 receptor as a target for cancer therapy Expert. Opin. Ther. Targets 2005, 9, 753-768
26. Miller, B. S.; Yee, D. Type I insulin-like growth factor receptor as a therapeutic target in cancer Cancer Res. 2005, 65, 10123-10127
27. Ueda, S.; Hatsuse1, K.; Tsuda, H.; Ogata, S.; Kawarabayashi, N.; Takigawa, T.; Einama, T.; Morita, D.; Fukatsu1, K.; Sugiura, Y.; Matsubara, O.; Mochizuki, H. Potential crosstalk between insulin-like growth factor receptor type 1 and epidermal growth factor receptor in progression and metastasis of pancreatic cancer Mod. Pathol. 2006, 19, 788-796
28. A previously described hierarchical molecular modeling method was used for generating the docked models: Lee, M. R.; Sun, Y. Improving Docking Accuracy through Molecular Mechanics Generalized Born Optimization and Scoring J. Chem. Theory Comput. 2007, 3, 1106
29. Unpublished results. Published DFG-out X-ray structures of c-Met inhibitors include
30. Kim, K. S.; Zhang, L.; Schmidt, R.; Cai, Z. W.; Wei, D.; Williams, D. K.; Lombardo, L. J.; Trainor, G. L.; Xie, D.; Zhang, Y.; An, Y.; Sack, J. S.; Tokarski, J. S.; Darienzo, C.; Kamath, A.; Marathe, P.; Zhang, Y.; Lippy, J.; Jeyaseelan, R.; Wautlet, B.; Henley, B.; Gullo-Brown, J.; Manne, V.; Hunt, J. T.; Fargnoli, J.; Borzilleri, R. M. Discovery of pyrrolopyridine-pyridone based inhibitors of Met kinase: synthesis, X-ray crystallographic analysis, and biological Activities J. Med. Chem. 2008, 51, 5330-5341
31. Qian, F.; Engst, S.; Yamaguchi, K.; Yu, P.; Won, K.-A.; Mock, L.; Lou, T.; Tan, J.; Li, C.; Tam, D.; Lougheed, J.; Yakes, F. M.; Bentzien, F.; Xu, W.; Zaks, T.; Wooster, R.; Greshock, J.; Holy, A. H. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases Cancer Res. 2009, 69, 8009-8016
32. Lin, A. J.; Loo, T. L. Synthesis and antitumor activity of halogen-substituted 4-(3,3-dimethyl-1-triazeno)quinolines J. Med. Chem. 2002, 21, 268-272
33. Samizu, K.; Hisamichi, H.; Matsuhisa, A.; Kinoyama, I.; Hayakawa, M.; Taniguchi, N.; Ideyama, Y.; Kuromitsu, S.; Yahiro, K.; Okada, M. Preparation of 3-quinoline-2(1 H)-ylideneindolin-2-one derivatives as vascular endothelial growth factor (VEGF) inhibitors. Patent WO 2002/094809A1, 2002.
34. Herbert, J. M. Negishi-type coupling of bromoarenes with dimethylzinc Tetrahedron Lett. 2004, 45, 817-819
35. Molander, G. A.; Rivero, M. R. Suzuki Cross-coupling reactions of potassium alkenyltrifluoroborates Org. Lett. 2002, 4, 107-109
36. Kubo, K.; Shimizu, T.; Ohyama, S.-I.; Murooka, H.; Iwai, A.; Nakamura, K.; Hasegawa, K.; Kobayashi, Y.; Takahashi, N.; Takahashi, K.; Kato, S.; Izawa, T.; Isoe, T. Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N -phenyl- N ′-{4-(4-quinolyloxy)phenyl}ureas J. Med. Chem. 2005, 48, 1359-1366
37. Bannen, L. C.; Chan, D. S.-m.; Chen, J.; Dalrymple, L. E.; Forsyth, T. P.; Huynh, T. P.; Jammalamadaka, V.; Khoury, R. G.; Leahy, J. W.; Mac, M. B.; Mann, G.; Mann, L. W.; Nuss, J. M.; Parks, J. J.; Takeuchi, C. S.; Wang, Y.; Xu, W. Preparation of quinolines and quinazolines as inhibitors of c-Met and other tyrosine kinases and therapeutic uses against proliferative diseases. Patent WO 2005/030140, 2005.
38. Kung, P. P.; Funk, L.; Meng, J.; Alton, G.; Padrique, E.; Mroczkowski, B. Structure activity relationships of quinoline-containing c-Met inhibitors Eur. J. Med. Chem. 2008, 43, 1321-1329
39. Lauer, W. M.; Arnold, R. T.; Tiffany, B.; Tinker, J. Synthesis of some chloromethoxyquinolines J. Am. Chem. Soc. 1946, 68, 1268-1269
40. Nara, S. J.; Jha, M.; Brinkhorst, J.; Zemanek, T. J.; Pratt, D. A. A simple Cu-catalyzed coupling approach to substituted 3-pyridinol and 5-opyrimidinol antioxidants J. Org. Chem. 2008, 73, 9326-9333
41. Ledrut, J.; Combes, G. Reaction of N -bromosuccinamide with pyrazolones Comptes Rendus 1950, 231, 1513-1515
42. de Graef, H.; Ledrut, J.; Combes, G. Prazolone series. XI. Reaction of N -halo imides with antipyrine and derivatives Bull. Soc. Chim. Belges 1952, 61, 331-351
43. Ito, I.; Oda, N. Synthesis of pyrazolone derivatives. XI. Synthesis of 6-substituted 1,2,6,7-tetrahydro-3 H -pyrazolo[4,3- c ]pyridine Chem. Pharm. Bull. 1966, 14, 297-298 and references cited therein.
44. Bodendorf, K.; Mildner, J.; Lehmann, T. Über Antipyrinaldehyd und Antipyrinsaure Eur. J. Org. Chem. 1949, 563, 1-11
45. Brooks, D. W.; Lu, L. D.-L.; Masamune, S. C-Acylation under virtually neutral conditions Angew. Chem. Int Ed. 1979, 18, 72-74
46. Barluenga, J.; Merino, I.; Viña, S.; Palacios, F. Regioselective synthesis of 1-alkyl-1-phenylhydrazines, 2-alkyl-1-phenylhydrazines, and 1,2-dialkyl-1-phenylhydrazines Synthesis 1990, 398-400
47. Rockley, J. E.; Summers, L. A. Structures of 5-Methyl-4-((arylamino) methylene)-2,4-dihydro-3 H -pyrazol-3-ones Aust. J. Chem. 1981, 34, 1117-1124
48. Bal, B. S.; Childers, W. E., Jr.; Pinnick, H. W. Tetrahedron 1981, 37, 2091-2096
49. Siegmund, A.; Retz, D.; Xi, N.; Dominguez, C.; Burli, R.; Liu, L. Selective β-hydroxyethylation at the N-1 position of a pyrazolone: synthesis of benzyl 1-(β-hydroxyethyl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro- 1 H -pyrazole-4-carboxylate Synlett 2008, 1005-1008
50. Bridges, A. J.; Zhou, H.; Cody, D. R.; Rewcastle, G. W.; McMichael, A.; Showalter, H. D. H.; Fry, D. W.; Kraker, A. J.; Denny, W. A. Tyrosine kinase inhibitors: unusually steep structure-activity relationship for analogs of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor J. Med. Chem. 1996, 39, 267-76
51. Wissner, A.; Berger, D. M.; Boschelli, D. H.; Floyd, M. B., Jr.; Greenberger, L. M.; Gruber, B. C.; Johnson, B. D.; Mamuya, N.; Nilakantan, R.; Reich, M. F.; Shen, R.; Tsou, H.-R.; Upeslacis, E.; Wang, Y. F.; Wu, B.; Ye, F.; Zhang, N. 4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7-dialkoxyquinazoline inhibitors J. Med. Chem. 2000, 43, 3244-3256
52. Scott, D. A.; Balliet, C. L.; Cook, D. J.; Davis, A. M.; Gero, T. W.; Omer, C. A.; Poondru, S.; Theoclitou, M.-E.; Tyurin, B.; Zinda, M. J. Identification of 3-amido-4-anilinoquinolines as potent and selective inhibitors of CSF-1R kinase Bioorg. Med. Chem. Lett. 2009, 19, 697-700
53. Cincinelli, R.; Cassinelli, G.; Dallavalle, S.; Lanzi, C.; Merlini, L.; Botta, M.; Tuccinardi, T.; Martinelli, A.; Penco, S.; Zunino, F. Synthesis, modeling, and RET protein kinase inhibitory activity of 3- and 4-substituted b-Carbolin-1-ones J. Med. Chem. 2008, 51, 7777-7787
54. Kim, K.-H.; Wissner, A.; Floyd, M. B., Jr.; Fraser, H. L.; Wang, Y. D.; Dushin, R. G.; Hu, Y.; Olland, A.; Guo, B.; Arndt, K. Benzo[ c ][2,7]naphthyridines as inhibitors of PDK-1 Bioorg. Med. Chem. Lett. 2009, 19, 5225-5228
55. Flowers-Geary, L.; Harvey, R. G.; Penning, T. M. Cytotoxicity of polycyclic aromatic hydrocarbon o -quinones in rats and human hepatoma cells Chem. Res. Toxicol. 1993, 6, 252-260
56. Evans, D. C.; Watt, A. P.; Nicoll-Griffith, D. A.; Baillie, T. A. Drug-protein adducts: an industry prespective on minimizing the potential for drug bioactivation in drug discovery and development Chem. Res. Toxicol. 2004, 17, 3-16
57. Nelson, S. D. Metabolic activation and drug toxicity J. Med. Chem. 1982, 25, 753-765
58. This strategy was recently applied to an acylthiourea series: Kung, P.-P.; Funk, L.; Meng, J.; Alton, G.; Padrique, E.; Mroczkowski, B. Structure-activity relationships of quinoline-containing c-Met inhibitors Eur. J. Med. Chem. 2008, 43, 1321-1329
59. Zhang, Y.; Kaplan-Lefko, P. J.; Rex, K.; Yang, Y.; Moriguchi, J.; Osgood, T.; Mattson, B.; Coxon, A.; Reese, M.; Kim, T.-S.; Lin, J.; Chen, A.; Burgess, T. L.; Dussault, I. Identification of a novel Recepteur d'Origine Nantais/c-Met small molecule kinase inhibitor with antitumor activity in vivo Cancer Res. 2008, 68, 6680-6687
60. Part of the synthesis and characterization of compounds have been described in: Kim, T.-S.; Bauer, D.; Bellon, S.; Boezio, A.; Booker, S.; Choquette, D.; D'Amico, D. C.; D'Angelo, N.; Dominguez, C.; Fellows, I. M.; Germain, J.; Graceffa, R.; Harmange, J.-C.; Hirai, S.; La, D.; Lee, M.; Liu, L.; Norman, M. H.; Potashman, M.; Rovet, P.; Siegmund, A. C.; Xi, N.; Yang, K. (Amgen Inc). Patent WO 2006/116713A1, 2006.
61. Kubo, K.; Shimizu, T.; Ohyama, S.-I.; Murooka, H.; Iwai, A.; Nakamura, K.; Hasegawa, K.; Kobayashi, Y.; Takahashi, N.; Takahashi, K.; Kato, S.; Izawa, T.; Isoe, T. Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N -phenyl- N ′-{4-(4-quinolyloxy)phenyl}ureas J. Med. Chem. 2005, 48, 1359-1366